| Expression pattern: |
UP |
| Associated gene: |
GPCPD1, lysophosphatidic acid (LPA) |
| Associated microRNA: |
miR-1184 |
| Biological function: |
circSNX6 mediates sunitinib resistance in RCC; silencing circSNX6 enhances sunitinib sensitivity, promotes apoptosis, induces mitochondrial changes, and inhibits tumor growth in vivo. |
| Molecular mechanism: |
circSNX6 contributes to sunitinib resistance through the miR-1184/GPCPD1/lysophosphatidic acid (LPA) axis and may influence mitochondrial organization and apoptosis-related gene expression; HA-PLGA nanoparticles deliver circSNX6 siRNA to silence circSNX6 in CD44-positive RCC cells. |
| Biological pathway or process: |
drug resistance (promotes); apoptosis (inhibits); mitochondrial function (other); ceRNA regulation (other) |
| Detected method: |
S
|
| Validation methods: |
RNA-seq; Bioinformatics Analysis; Transfection; CCK8; Annexin V/PI Flow Cytometry; IF (Immunofluorescence); In Vivo Animal Model |
| Clinical significance: |
Elevated circSNX6 expression was associated with poor clinical outcomes in RCC patients. |
| Description: |
This study investigated circSNX6 as a therapeutic target for sunitinib-resistant renal cell carcinoma. HA-PLGA nanoparticles carrying circSNX6 siRNA sensitized resistant RCC cells to sunitinib, promoted apoptosis, altered mitochondrial organization-related programs, and inhibited tumor growth in a xenograft model. The paper also links circSNX6 to the miR-1184/GPCPD1/LPA axis and poor clinical outcomes in RCC patients. |
| Confidence score: |
0.4611 |